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Abstract A highly efficient recognition unit based on
surface-enhanced Raman spectroscopy (SERS) was devel-
oped as a promising, fast, and sensitive tool for detection of
meningococcal meningitis, which is an extremely serious and
often fatal disease of the nervous system (an inflammation of
the lining around the brain and spinal cord). The results of this
study confirmed that there were specific differences in SERS
spectra between cerebrospinal fluid (CSF) samples infected
by Neisseria meningitidis and the normal CSF, suggesting a
potential role for neopterin in meningococcal meningitis de-
tection and screening applications. To estimate the best per-
formance of neopterin as a marker of bacterial infection, prin-
cipal component analysis (PCA) was performed in a selected
region (640–720 cm−1) where the most prominent SERS peak
at 695 cm−1 arising from neopterin was observed. The calcu-
lated specificity of 95 % and sensitivity of 98 % clearly indi-
cate the effective diagnostic efficiency for differentiation be-
tween infected and control samples. Additionally, the limit of
detection (LOD) of neopterin in CSF clinical samples was
estimated. The level of neopterin was significantly higher in
CSF samples infected by N. meningitidis (48 nmol/L), com-
pared to the normal (control) group (4.3 nmol/L).
Additionally, this work presents a new type of SERS-active
nanostructure, based on polymer mats, that allows simulta-
neous filtration, immobilization, and enhancement of the
Raman signal, enabling detection of spectra from single bac-
terial cells of N. meningitidis present in CSF samples. This
provides a new possibility for fast and easy detection of bac-
teria in CSF and other clinical body fluids on a time scale of
seconds. This method of detection produces consistent results
faster and cheaper than traditional laboratory techniques, dem-
onstrates the powerful potential of SERS for detection of dis-
ease, and shows the viability of future development in
healthcare applications.
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trihydroxypropyl)pteridine) is produced from guanosine tri-
phosphate by human monocytes and macrophages after stim-
ulation by interferon gamma (IFN-γ) derived from antigen-
activated T lymphocytes [1, 2]. After activation of the immune
system the level of neopterin in human body fluids is signif-
icantly increased. Thus, determination of neopterin may indi-
cate the state of activation of the cellular immune system dur-
ing subsequent stages of various diseases, such as rheumatoid
arthritis (RA) [3], neuropsychiatric abnormalities [4], cardio-
vascular disease [5], insulin resistance [6], allograft rejection,
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and some tumors [7]. Elevated neopterin levels were also ob-
served in viral infections [8–11] (hepatitis A, B, and C, cyto-
megalovirus, measles, rubella, influenza), and bacterial infec-
tions [12]. In patients with sepsis (a consequence of metabolic
and hemodynamic events caused bymicrobial invasion), plas-
ma concentrations of neopterin are increased compared with
healthy controls [13].
Bacterial meningitis might be associated with both, elevat-
ed serum and cerebrospinal fluid (CSF) neopterin levels com-
pared to controls [10, 14, 15]. In brucellosis, neopterin levels
were a mean of 52.5 mmol/mL, significantly higher than for
healthy controls (<5 nmol/L) and patients with tuberculosis
[16]. In leprosy caused by Mycobacterium leprae, 75 % of
patients with tuberculoid and lepromatous leprosy presented
elevated urinary neopterin excretion [17].
In the context of rising drug resistance and difficulties in
monitoring drug compliance, a new diagnostics marker needs
to be explored. It may also be useful to distinguish active
forms of disease from latent ones. Within the group of bacte-
rial infections it was shown that patients with symptoms last-
ing for at least 5 days had significantly higher neopterin con-
centrations than patients with acute illness. Investigations on
critically ill patients in intensive care units evaluated neopterin
levels as a tool to discriminate patients with systemic inflam-
matory response syndrome with and without infectious etiol-
ogy. Neopterin levels were found to have a specificity of 78 %
for discriminating infectious and noninfectious etiology of
critical illness [18].
The measurement of the neopterin levels can provide reli-
able information regarding the disease diagnosis, stage, prog-
nosis, and is also important for monitoring the response to
therapy. Screening of neopterin concentrations in blood dona-
tions allows one to detect acute infections in a nonspecific way
and improves safety of blood transfusions. Up to now several
analytical procedures have been applied for evaluation of the
neopterin level in blood using mainly high pressure liquid
chromatography (HPLC) [19] and enzyme-linked immuno-
sorbent assay (ELISA) [20] techniques.
However, both of these methods are effortful and expen-
sive, andmoreover they require technical equipment and high-
ly qualified personnel. Additionally, the difficulties and inac-
curacy of existing neopterin assays have been presented, and a
number of factors have been shown to affect the validity and
quality of such measurements [21–23]. To the best of our
knowledge, all immunoassays which are used for this immune
marker are at or near their limit of measurement. Therefore,
there is a need to develop a more sensitive, selective, stable,
and durable method for the specified biomarkers.
As was mentioned, the main method for determination of
the selected immune markers relies heavily on various ELISA
kits. Alternative approaches during recent decades have usu-
ally used fluorescent antibody assays, evanescent wave inter-
ference, and electrochemical methods. Current successes in
nanotechnology and instrumentation development have led
to recognition of biomolecular systems based on surface-
enhanced Raman spectroscopy (SERS) with a higher sensitiv-
ity and a more clear visualization of bioanalytes. In brief,
surface-enhanced Raman scattering is a vibrational spectros-
copy that relies on enhancement of the electromagnetic field
due to resonance between the excitation light and surface
plasmons of the SERS nanostructures [24, 25]. This electro-
magnetic effect is the main contributor in SERS enhancement
and may increase the Raman signal up to 1011-fold. A chem-
ical mechanism is also believed to take place in SERS en-
hancement owing to the charge transfer between adsorbed
molecules and the metal conduction band of metallic nano-
structures. This chemical mechanism may provide an en-
hancement factor (EF) of less than 4 orders of magnitude
[26, 27]. Both these mechanisms ensure enhancement of
Raman signal with single molecule resolution [28]. Another
interesting point about SERS is the linear dependence of
SERS intensity on the power of incident light despite the
extraordinary nonlinear effect of signal enhancement.
Therefore, SERS technology can be used for the quantitative
measurement of analytes with ultrahigh sensitivity [29]. The
SERS technique therefore extends the range of Raman appli-
cations to more sensitive, specific, and fast detection of a wide
range of analytes, e.g., nucleic acids and proteins [30], thera-
peutic agents [31], drugs and trace materials [32], microorgan-
isms [33], and cells [34].
In this study we present our research efforts aimed at de-
tection of specific bacterial infection caused by Neisseria
meningitidis using surface-enhanced Raman spectroscopy.
Anton Weichselbaum first isolated N. meningitidis from
the CSF of a patient [35]. This bacterium is a Gram-
negative diplococcus and belongs to pathogenic members
of the Neisseriaceae family [36]. N. meningitidis is one of
the three main bacteria that cause acute bacterial meningitis,
along with Streptococcus pneumoniae and Haemophilus
influenzae [37].
N. meningitidis only infects humans and the average
incubation period is 4 days, but it can range between 2
and 10 days. Meningitis caused by this bacteria is usu-
ally very serious (5 % to 10 % of patients die, typically
within 24 to 48 h after the onset of symptoms) and re-
quires rapid detection and urgent medical attention with
appropriate antibiotic therapy. Taking into account the
high mortality rates, rapid detection of bacteria in CSF
and subsequent effective treatment are essential.
In this work we present also, for the first time, the possibil-
ity of using neopterin levels for diagnosis of meningococcal
meningitis disease in CSF clinical samples already diagnosed
by microbiological techniques. Additionally, the obtained re-
sults were compared with ELISA as the reference method. We
use SERS combined with a multivariate statistical method
(principal component analysis, PCA) to differentiate between
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CSF control clinical samples (from healthy patients) and CSF
clinical samples infected by N. meningitidis. Moreover, be-
sides the Si/ZnO/Au platform used for neopterin level calcu-
lation, a new SERS substrate based on a polymer mat was
applied for simultaneous filtration, immobilization, and en-




Neopterin was purchased from Tocris Bioscience (Bristol,
UK). Water (resistivity over 18 MΩ cm) was purified
using a Milli-Q plus 185 system and used in all exper-
iments. The CSF and N. meningitidis strain were obtain-
ed from the National Reference Centre for Bacterial
Meningitis (NRCBM) in the National Medicines Institute
(NMI) in Warsaw. The neopterin levels in CSF were esti-
mated by a commercial ELISA test (IBL International
GmbH, Hamburg).
Instrumentation and data collection
Raman and SERS spectra of analyzed samples were recorded
using the Renishaw inVia Raman system with 1024×256 pixel
Peltier-cooled RenCam CCD detector. All measurement were
performed using ×20 microscope objective (numerical aper-
ture=0.25), focusing the 785-nm laser to a spot size of approx-
imately 5 μm. SERS spectra were acquired from less than
5 mW of incident laser power at ambient conditions using a
back-scattering geometry. The SERS spectra were recorded be-
tween 400 and 1600 cm−1 at resolution of ca. 2 cm−1. The
typical acquisition time was 10 s for a single SERS measure-
ment. The obtained spectra were processed with OPUS soft-
ware provided by Bruker. All spectra were smoothed, baseline
corrected, and normalized.
SEM measurements were conducted using the FEI Nova




Atomic layer deposition (ALD) was used for zinc oxide layer
deposition on Si(100) at 100 °C. Diethylzinc and deionized
water were used as precursors, and nitrogen was used as purg-
ing gas [29]. The process was conducted in the Savannah-100
reactor. Typically the ZnO layers were grown with 10,000
ALD cycles, which lead to approximately 1.4 μm thickness.
Electrospun polymer mats
The poly(L-lactide) (PLA) mats were purchased from MECC
Co., Ltd., Japan and cut into squares (area of 0.25 cm2).
Procedure for SERS nanostructure gold sputtering
Si/ZnO layers and electrospun polymer mats were covered
with a thin layer of sputtered gold (ca. 90 nm) using PVD
equipment from Leica (model EM MED020). Au target was
obtained from Mennica Metale Szlachetne, Warsaw, Poland.
During this procedure a vacuum level of 10−2 mbar and cur-
rent of 25 mAwere applied.
Bacterial sample preparation for microbiological
and SERS experiments
Clinical CSF samples were obtained as a part of routine activ-
ity of the NRCBM and were analyzed anonymously. All the
data were collected in accordance with the European
Parliament and Council decision for the epidemiological sur-
veillance and control of communicable disease in the
European Community [38, 39]. Thus ethical approval and
informed consent were not required. N. meningitidis of
serogroup B (603/2011) used during the study serves as a
reference strain in polymerase chain reaction (PCR) in the
NRCBM.
Microbiological confirmation of N. meningitidis
In the case of negative culture, the NRCBM has been receiv-
ing clinical materials, including CSF, from patients with
suspected invasive meningococcal disease. The DNA isolated
from these samples was used for PCR to identify N.
meningitidis [40, 41].
The strain was identified on the basis of typical morpholo-
gy of colonies, Gram stain, oxidase test, and API NH test
(bioMerieux, Marcy-l’Etoile, France) according to the manu-
facturer’s instructions. Serogroup was determined by slide
agglutination tests using commercial antisera (Remel).
Bacterial culture and SERS sample preparation
Neisseria meningitidis used in the experiment was obtained
from the NRCBM in Warsaw, Poland. To multiply microbial
organisms, we cultivated them on solid BHI (brain heart infu-
sion) growth medium at 37 °C for 24 h. After that, some
bacterial colonies were redispersed in saline solution (sterile
0.9 % NaCl solution) and centrifuged for 5 min at 4000 rpm
(so as not to destroy the cell membrane). The centrifugation
process in the fresh saline solution was repeated four times to
obtain a solution of clean bacterial cells, at a concentration of
N. meningitidis of 106 CFU/mL. The density of bacterial cells
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was determined by counting the amount of colonies which
had grown on the Petri dish from a known amount of medium.
The count was taken after 1 day of cultivation at 37 °C. Before
carrying out Raman measurements, 10 μL of an aqueous bac-
terial solution was placed over the SERS substrate.
Measurements were taken after 5 min.
Chemometrics
The SERS spectra were prepared for PCA using a two-
step approach. First, OPUS software (Bruker Optic GmbH
2012 version) was used to smooth the spectra with the
Savitsky–Golay filter, the background was removed using
baseline correction, and then the spectra were normalized
using a so-called Min-Max normalization (the area of
band around 963 cm−1). All the data were transferred to
the Unscrambler software (CAMO software AS, version
10.3, Norway) where PCA was performed. PCA is a mul-
tivariate technique that reduces the dimensionality of
complex spectroscopic data from many wavenumber as-
signments to a few principal components (PCs), making it
easier to identify the majority of variations within the
spectra [42].
PCA reduces the complexity of high-dimensional SERS
data from many wavenumber assignments to several PCs.
Each PC represents a linear combination of the original
variables (e.g., Raman wavenumber). The first compo-
nent (in the horizontal direction) is the most important
one and accounts for as much variation in the data as
possible. In the PCA model, the big spectral set matrix
(X) is transformed into two smaller matrices according to
the formula X = TPT + E where T is the matrix of
scores, P is the matrix of loadings, and E is the error
matrix. The PCA method enables one to understand the
sources of variation in the obtained SERS data, e.g., the
plot of loadings vs. the wavenumber indicates the most
important diagnostic vibrations in the spectra.
In our study, PCA was carried on two different data
sets, consisting of spectra obtained for normal CSF
(without microbiological confirmation of N. meningitidis
infection) and for CSF infected by this pathogen.
Additionally, the obtained data allow one to calculate
the diagnostic sensitivity and specificity according to
the formula [43]
Sensitivity ¼ TP= TPþ FNð Þ
Specificity ¼ TN= TNþ FPð Þ
where TP and TN are the numbers of true positive and
true negative results, respectively; FN and FP are the
numbers of false negative and false positive results,
respectively.
Results and discussion
SERS analysis of CSF and neopterin: comparison
between normal healthy control and
N. meningitidis-infected clinical samples
Neopterin appears in human CSF, blood (plasma, serum), and
urine, and its increased levels indicate activation of the im-
mune system involved in the pathogenesis and/or affected by
malignant diseases. An earlier literature report [44] reveals
that CSF neopterin characterization at different stages of
HIV infection can serve as a useful method for the diagnosis
of this disease and in monitoring the central nervous system
inflammatory effects; it can also give valuable information
regarding the cause of ongoing brain pathology. Our results
showed that neopterin is biologically and chemically stable as
a biomarker in human biological fluids, gives very strong
SERS signals, and it can be easily quantified using SERS.
The inset in Fig. 1 presents the SERS spectrum of neopterin
adsorbed onto the Si/ZnO/Au substrate from 35.0 nmol/L
neopterin solution in a PBS buffer. The morphological struc-
ture of the Si/ZnO/Au platform is presented in Fig. 2. The
SERS spectrum of neopterin is dominated by bands at 695,


































































































Fig. 1 Comparison of the SERS spectrum of the CSF samples infected
by N. meningitidis (a) versus that of the normal (control) CSF samples
(b). Samples of CSF were deposited onto the Si/ZnO/Au substrate and
measured in situ. The inset shows the SERS spectrum of neopterin
adsorbed onto the Si/ZnO/Au substrate from 35.0 nmol/L neopterin
solution in a PBS buffer. The presented SERS spectra were averaged from
ten measurements in different places of the SERS nanostructures
4322 A. Kamińska et al.
1308, and 1578 cm−1 due to C–C vibration and ring modes, N–
H bending modes, and NH2 symmetric deformation, respec-
tively [45]. In this work we examine the CSF neopterin changes
in bacterial infections. SERS characterization of CSF samples
of both healthy subjects and patients with confirmed bacterial
meningitis was carried out. Figure 1 shows the normalized
SERS spectra of CSF samples infected by N. meningitidis
(1a) and the normal (control) CSF samples (1b) deposited onto
the Si/ZnO/Au substrate. CSF of the healthy patient contains no
erythrocytes and up to five leukocytes per microliter [46]. The
intense bands at 728, 1096, 1134, 1377, and 1596 cm−1 were
assigned to vibrations of the nucleic bases of DNA and lipids
[47]. The features at 1469, 1250, 1006, and 964 cm−1 are asso-
ciated with CH2 deformation, the amide III, the symmetric ring
breathing bands of phenylalanine and protein, and C–C
stretching, respectively [48]. Aromatic amino acid residues,
phenylalanine, tyrosine, and tryptophan were expected to have
bands at 625, 659, 866, 1173, and 1213 cm−1. The prominent
SERS peaks located at 659, 728, 963, 1006, 1096, 1134, and
1469 cm−1 can also be consistently observed in infected sam-
ples (Fig. 1b). However, a detailed analysis of SERS spectra of
CSF from patients affected by bacterial meningitis reveals
remarkable differences. The new SERS band at 695 cm−1
which corresponds to the C–C vibration and ring modes
of neopterin [49] can be observed only in the infected
samples and is absent in healthy subjects. This indicates
the increased contribution of neopterin in bacterial infec-
tions. In the range 500–1600 cm−1, SERS spectra of CSF
are complex and provide a rich source of information
about numerous CSF components. The region of CSF
(660–720 cm−1) in which the marker band of neopterin
appears (695 cm−1) is devoid of other intensive vibrations
and allows label-free analysis of neopterin. There are also
distinctive SERS features and intensity differences for
normal and infected CSF samples in the spectral ranges
of 1200–1260, 1270–1380, and 1500–1650 cm−1, indicat-
ed by the gray-shaded columns in Fig. 1. These differences in
the SERS spectral pattern could reflect changes in the quantity
and structure of proteins and peptides of CSF associated with
abnormal metabolism of patients with bacterial infections. For
example, in infected samples the bands at 1213 and 1250 cm−1
due to the C–H in-plane bending of phenylalanine and/or tyro-
sine and amide III band of proteins (α-helix) disappear and a
new band at around 1240 cm−1 is observed, indicating transi-
tion from an α-helical to β-sheet structure [50] of certain pro-
teins in infected CSF samples. Moreover, the SERS band of
tryptophan at 1572 cm−1 was found to be higher in normal CSF
samples, suggesting a decrease in the relative amount of tryp-
tophan and also larger amount of neutral amino acids like phe-
nylalanine, histidine, and isoleucine [51] in CSF with N.
meningitidis. It should be highlighted that these changes in
the three regions mentioned above appear only in real clinical
samples of CSF infected by N. meningitidis bacterium. Figure
S1 in the Electronic Supplementary Material (ESM) shows the
comparison of a SERS spectrum for a clinical sample of CSF
infected by N. meningitidis (b) versus that of normal CSF with
added 15 nmol/L solution of neopterin (a). As can be seen, for
samples of CSF with neopterin Bartificially^ inserted (ESM
Fig. S1) only the marker band at 659 cm−1 corresponding to
neopterin appears. The SERS differences that indicate the
changes in quantity and structure of proteins and peptides of
CSF (changes in the regions of 1200–1260, 1270–1380, and
1500–1650 cm−1) were not observed. This is clear evidence that
these spectral features are correlated only with anomalous me-
tabolism of patients with bacterial infection.
Chemometrics analysis
Although significant spectral differences between normal and
infected CSF have been clearly observed in SERS spectra, this
simplistic analysis of the experimental observations uses only
limited number of SERS peaks or SERS regions. Therefore,
multivariate statistical analysis in the form of PCA has been
exploited to utilize the whole spectra and to automatically
determine the diagnostic marker bands for improving the ef-
ficiency of CSF diagnosis and also to find out the statistical
significance of the proposed method. This analysis method is





Fig. 2 SEM images of the SERS nanostructures: (a) Au-coated Si/ZnO and (b) PLA polymer mat
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dimensionality of Raman data and is widely used by re-
searchers in discriminating cancer tissues from that of a con-
trol subject [52], for identification of pathogens in body fluids
[53], and for blood analysis [49].
The PCs are used to build a model with a resolution of
recognition. Initially, the analysis was performed in the whole
spectral region between 500 and 1650 cm−1. In the first step
we found that three PCs (PC1, PC2, PC3) are the most diag-
nostically significant and explain 94 % of the variance in the
data. The resulting PC scores plots (Fig. 3a, b) indicate diag-
nostic utility to differentiate between analyzed samples. As
can be seen, it is possible to separate the normal CSF data
points and N. meningitidis-infected CSF data points along
the axis of the first PC.
The loadings of the PCs provide information on the vari-
ables (wavenumber of the spectrum) that are important for
group separation. Figure 3c displays the loadings plots of
PC1 and PC2 for the whole wavenumber region 500–
1600 cm−1. By analysing these plots one can indicate the most
important diagnostic variables in the analyzed data set.
Variables with high loading values are the most important
for diagnostic purposes. The loadings of both PC1 and PC2
exhibit a positive peak attributed to the main marker bands of
the neopterin (Fig. 3c). That is why, for the best classification
among the two groups of analyzed samples, the PCA was
performed for the selected narrow region (640–720 cm−1)
where the most prominent SERS peak at 695 cm−1 arising
from neopterin is observed (see Fig. 1b and inset in Fig. 1).
Figure 4 displays the score plot of the first two principal
components PC1 (95 % of the total variance) and PC2 (2 % of
the total variance) of the normal CSF and N. meningitidis-
infected CSF SERS spectra. The stepwise analysis in this area
gives a more effective diagnostic efficiency for distinguishing
between infected and control samples. A specificity of 98 %
and sensitivity of 95 % were obtained. These results demon-
strate that the marker band of neopterin (695 cm−1) can be
used for meningococcal meningitis detection in CSF samples.
Measurement of neopterin concentration in CSF
The measurement of neopterin concentration in human body
fluids such as serum, urine pleural fluid, and CSF provides an
insight into cell-mediated immune responses. In this study we
also examined the neopterin levels in samples infected by N.
meningitidis and in healthy controls using the SERS technique.
Figure 5a presents the scheme of the detection mechanism of
Fig. 3 (a) Plot of the first principal component PC1 (83 % of the total
variance) versus the second principal component PC2 (9 % of the total
variance) and (b) plot of the first principal component PC1 (83 % of the
total variance) versus the third principal component PC3 (4 % of the total
variance) for the normal group versus infected group. (c) Loadings plots
of the first and second principal components PC1 and PC2, highlighting
regions associated with large loadings
Fig. 4 Scatter plots of the first two principal components PC1 (95 % of
the total variance) and PC2 (2 % of the total variance) of the scores
belonging to the control and N. meningitidis-infected CSF categories
for the 640–720 cm−1 diagnostic range
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neopterin applied in this experiment. The calibration curve was
built on the basis of the plot of SERS intensity (band at
695 cm−1) versus the concentration of neopterin in normal
CSF (Fig. 5b). The neopterin was artificially added to normal
CSF samples in clinically important concentrations (0.0–
90.0 nmol/L). The calibration curve was fitted over the analyzed
region (y=162.37x) and the correlation coefficient of 0.998 was
calculated. The linear dependence of the SERS intensity at
695 cm−1 (y) on the neopterin concentration (x) in the whole
examined region was evident. Moreover, the limit of detection
(LOD=1.6 nmol/L) was assessed on the basis of the signal-to-
noise method [54]. This calibration line was used to estimate the
concentrations of neopterin in clinical samples of CSF infected
by N. meningitidis. The neopterin concentrations of the same
samples were also evaluated using a commercial ELISA kit
(IBL International). Furthermore, the results were evaluated by
comparing with control samples and estimated values are de-
scribed in Table 1.
It should be highlighted that for normal healthy control
samples of CSF the level of neopterin was below 4.3 nmol/L.
A value below 5 nmol/L is a typical CSF neopterin concentra-
tion calculated for patients without a modified immune system
[14]. In contrast, CSF neopterin concentrations determined by
radioimmunoassay (RIA) were 63.0 nmol/L for patients with
acute bacterial meningitis, 32.5 nmol/L for patients with Lyme
neuroborreliosis, and 130.9 nmol/L in individuals with viral
meningitis [14].
These results clearly demonstrate that neopterin may be
used as a marker in the meningococcal meningitis diagnosis
and monitoring of this infection.
Detection of N. meningitidis in CSF
Surface-enhanced Raman spectroscopy is a powerful tech-
nique for the rapid and accurate detection of pathogenic bac-
teria in biological fluids [33]. In our laboratory, we have de-
veloped a new type of SERS nanostructure that permits the
simultaneous filtration of bacteria from solutions, immobiliza-
tion onto the SERS nanostructures, and their Raman signals
enhancement. The applied SERS substrate is based on a gold-
covered electrospun polymer mat [55]. The morphology of
this SERS substrate is presented in Fig. 2. In the present study
we used this SERS substrate for detection ofN.meningitidis in
CSF samples. The applied technique is simple, fast, and al-
lows filtration and/or concentration of CSF composites (leu-
kocytes, albumins, globulins, and bacteria) within a small area
of the SERS nanostructures. The setup for the proposed meth-
od consists of a Büchner flask, a filter funnel, and a vacuum
pump [55]. The detection of bacteria was performed in two
steps. In the first step, a single droplet of infected CSF was
placed on the SERS platform positioned on a Büchner flask.
The vacuum pump caused the movement of the fluid through
SERS-active polymer mat. In the next step, several droplets of
a PBS buffer solution (at about 0.3 μL) were passed through
the polymer mat in the same way. Taking into account the size
of pores in the polymer mat (about 3–5 μm) and the size of
CSF components (leukocytes from 10 up to 15 μm [56], al-
bumins from 3 to 10 nm [57]), and the size of N. meningitidis
bacterium, which ranges from 0.6 to 1.0 μm [58], we are able
to separate these species. The largest leukocytes (the main
component of CSF) remain on the polymer mat, while the
a b
A dilution series of Neopterin  in CSF (artificially added):
5, 7, 12, 20, 25, 30, 45, 60, 70, 90 nmol/L
Clinical samples of CSF infected 
by Neisseria meningitidis
Calibration curve (plot of the intensity of the 
marker band of Neopterin at 695 cm-1 versus 
its concentrations in CSF)
Concentration of Neopterin 
in clinical CSF samples
SERS analysis of spectral features focused 
on 695 cm-1 marker band intensity estimation
Fig. 5 (a) Scheme of the
detection mechanism of
neopterin. (b) The plot of the
marker band intensity (695 cm−1)
versus the neopterin
concentration in CSF. The error
bars indicate the standard
deviations from ten averaged
measurements
Table 1 CSF neopterin
concentration obtained using two
methods, SERS and ELISA
SERS (new method) ELISA (reference method)
Control CSF (nmol/L) 3.8 ± 0.7 4.0 ± 1.3
Infected CSF (nmol/L) (with Neisseria meningitidis) 30.0 ± 4.1 36.0 ± 5.2
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smaller proteins and bacteria pass through. Figure 6 shows the
SERS spectra of CSF infected with N. meningitidis after fil-
tration on the SERS polymer platform. Figure 6a present the
SERS spectrum of CSF components trapped on the SERS
platform. The observed spectral features are characteristic
for leukocytes (Sect. BMeasurement of neopterin concentra-
tion in CSF^ and Fig. 2). Figure 6b depicts the SERS spec-
trum of the remaining part of the filtrated solution deposited
again on the Si/ZnO/Au substrate. The Raman spectrum of N.
meningitidis has not been presented in the literature; therefore
we attempted, for the first time, the SERS measurements and
band assignments of this bacterium. Figure 6c presents the
SERS spectrum of N. meningitidis multiplied before SERS
experiment by cultivation in a liquid LB (Lysogeny broth)
growth medium and then deposited on the Si/ZnO/Au sub-
strate. As can be seen in Fig. 6c, the intense band at about
736 cm−1 appears in the SERS spectrum of N. meningitidis.
This band is observed in many types of bacterial species like
Escherichia coli, Salmonella enterica, Staphylococcus
epidermidis, Staphylococcus aureus , and Bacillus
megaterium [33, 55]. This band is due to the C–N stretching
mode vibration of the adenine of lipid layer in the cell wall or
to the breathing mode of the purine ring [59, 60]. Jarvis et al.
assigned this band to the vibration of the glycosidic ring mode
from cell wall components [61]. Typical Raman bands of pro-
teins, phospholipids, and polysaccharides can be also ob-
served in the SERS spectrum of N. meningitidis. The other
observed bands can be attributed to amino acids (tyrosine,
phenylalanine), or to C–C vibrations in phosphate binding of
DNA, respectively [61].
The SERS spectrum of this bacterium also indicates peaks
assigned to amide III (1252 cm−1) and CH2 vibrations
(1450 cm−1) [59]. Table S1 (see ESM) shows band assign-
ments for N. meningitidis. The most intense bands at 736,
1002, 1330, and 1450 cm−1 were also observed in the remain-
ing part of a filtrated solution where the presence of, inter alia,
bacteria is expected (Fig. 6b). As exemplified by Fig. 6, we are
able to detect and identify the bacterial cell from CSF samples
using our novel SERS substrates.
Conclusions
This work presents a new label-free method for neopterin detec-
tion based on the SERS technique and the possibility of using
this method for determination of the neopterin levels in CSF. It
was also shown that CSF neopterin evaluation may be used in
determining the bacterial meningitis infections caused by N.
meningitidis.Additionally, a new class of SERS substrates based
on a polymer mat was developed for simultaneous filtration,
immobilization, and enhancement of the Raman signal, which
allows the detection of single bacterial cells of N. meningitidis
present in CSF samples. This opens a new route for simple
identification of bacteria in CSF and other clinical body fluids
on a time scale of seconds. In conclusion, neopterin emerges as
an important biomarker and a strong predictor of bacterial men-
ingitis infections. In the very near future, this study will be ex-
tended to a larger number of clinical samples to improve the
diagnostic sensitivity and selectivity.
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Fig. 6 The SERS spectrum of (a) CSF components trapped on a polymer
mat-based SERS platform, (b) the remaining part of the filtrated solution
deposited again on the Si/ZnO/Au substrate, and (c) the SERS spectrum
of N. meningitidis multiplied before SERS experiment by cultivation in
liquid LB (Lysogeny broth) growth medium and then deposited onto the
Si/ZnO/Au substrate
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